Targeting SHP2: Dual breakthroughs in colorectal cancer therapy-from signaling pathway modulation to immune...

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• SHP2 is an oncogenic tyrosine phosphatase overexpressed in colorectal cancer (CRC).
• SHP2 promotes CRC progression by mediating receptor tyrosine kinase (RTK) signaling pathways (RAS/ERK, JAK/STAT, PI3K/AKT).
• SHP2 contributes to an immunosuppressive tumor microenvironment (TME) by affecting T cell infiltration and tumor-associated macrophages.

Purpose of the Study:

• To highlight SHP2 as a dual therapeutic target in CRC.
• To emphasize SHP2's role in both RTK signaling and TME modulation.
• To underscore the clinical relevance of SHP2 inhibitors in CRC treatment.

Main Methods:

• Review of SHP2's role in CRC oncogenesis and TME.
• Analysis of SHP2's involvement in key signaling pathways.
• Evaluation of SHP2 inhibitors in preclinical and clinical settings.

Main Results:

• SHP2 overexpression is linked to poor prognosis in CRC patients.
• Targeting SHP2 simultaneously impacts oncogenic signaling and the TME.
• SHP2 inhibitors show promise as monotherapy and combination treatments.

Conclusions:

• SHP2 is a critical molecular target for precision oncology in CRC.
• SHP2 acts as an immunomodulatory node, making it a high-priority target for CRC therapy.
• SHP2 inhibitors represent a promising therapeutic strategy for colorectal cancer.